Neurocrine Biosciences Inc (NBIX): Shareholders' Equity
$3.25B
As of 2025-12-31
$3.69B
As of 2026-06-30
+24.0%
3-year compound annual growth
+23.6%
5-year compound annual growth
+22.6%
10-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $3.25B | +25.6% | 2026-02-11, Balance as of period end |
| 2024-12-31 | $2.59B | +16.0% | 2026-02-11, Balance as of period end |
| 2023-12-31 | $2.23B | +30.7% | 2026-02-11, Balance as of period end |
| 2022-12-31 | $1.71B | +24.3% | 2025-02-10, Balance as of period end |
| 2021-12-31 | $1.37B | +22.0% | 2024-02-09, Balance as of period end |
| 2020-12-31 | $1.13B | +76.8% | 2023-02-09, Balance as of period end |
| 2019-12-31 | $636.90M | +32.5% | 2022-02-11, Balance as of period end |
| 2018-12-31 | $480.80M | +29.2% | 2021-02-05, Balance as of period end |
| 2017-12-31 | $372.14M | +18.2% | 2020-02-07, Balance as of period end |
| 2016-12-31 | $314.88M | -25.8% | 2019-02-08, Balance as of period end |
| 2015-12-31 | $424.45M | +103.4% | 2018-02-13, Balance as of period end |
| 2014-12-31 | $208.70M | +73.3% | 2017-02-14, Balance as of period end |
| 2013-12-31 | $120.41M | -22.0% | 2016-02-11, Balance as of period end |
| 2012-12-31 | $154.37M | +156.9% | 2015-02-09, Balance as of period end |
| 2011-12-31 | $60.08M | +210.6% | 2014-02-11, Balance as of period end |
| 2010-12-31 | $19.34M | +389.3% | 2013-02-08, Balance as of period end |
| 2009-12-31 | $3.95M | n/a | 2012-02-09, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $3.25B | +25.6% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $2.16B | -3.7% |
| Qiagen N.V. (QGEN) | 2025-12-31 | $3.78B | +5.9% |
| Moderna, Inc. (MRNA) | 2025-12-31 | $8.65B | -20.6% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $48.81M | -86.6% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $2.11B | +9.9% |
| Novavax Inc (NVAX) | 2025-12-31 | -$127.75M | n/m |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | -$119.15M | n/m |
| Biogen Inc. (BIIB) | 2025-12-31 | $18.26B | +9.2% |
Compare NBIX, EXEL, QGEN, MRNA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗